Oncimmune launched the EarlyCDT-Liver test for hepatocellular carcinoma carcinoma in the US. The test has a specificity of 97 percent and is the second test launched by Oncimmune based on the EarlyCDT technology. EarlyCDT-Liver is a simple blood test and complementary to imaging-based testing. It can aid in stratifying high-risk patients whose diagnosis is indeterminate following ultrasound and CT or MRI. It can also aid in the risk assessment and early detection of HCC in high-risk patients with hepatic lesions less than 1 cm, Oncimmune said. The company has begun CE marking for a kit version of the test, which is expected to be completed by the end of Q1 2019.